Cambrex Expands Analytical Capabilities at its High Point, NC Site

East Rutherford, NJ – December 11, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing $1 million at its High Point, NC site to fit out 1,300 sq. ft. of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project. This investment follows the new $3.2 million, 11,000 sq. ft. analytical laboratory, completed in April 2018.

The expansion and fit out, which will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments, is set to be completed by year-end 2018.

“Cambrex is seeing a significant increase in new projects, resulting in increased demand for analytical development capabilities within the Cambrex organization,” commented Brian Swierenga, VP, Operations and Site Director for Cambrex High Point. He added, “This further expansion will not only increase Cambrex’s internal analytical capabilities and capacity, but will assist in getting new products to commercial launch faster.”

At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhanced Cambrex’s portfolio of small molecule API services and complements its large scale, multi-purpose manufacturing facilities in the US and Europe.

This latest expansion at the 35,000 sq. ft. facility brings the investment at the site to over $9 million since the acquisition of PhamaCore by Cambrex in 2016.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), finished dosage forms, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit


Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155

Posted by Hannah McLachlan